New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:25 EDTNLNK, NLNKNewLink Genetics management to meet with Jefferies
Meeting to be held in San Francisco on January 4 hosted by Jefferies.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
07:44 EDTNLNKNewLink Genetics price target raised to $48 from $41 at Cantor
Cantor increased its price target on NewLink (NLNK) after the company licensed its Ebola vaccine program to Merck (MRK) for an up-front payment and tiered royalties. The firm keeps a Buy rating on NewLink.
November 24, 2014
10:55 EDTNLNKNewLink Genetics January and April volatility elevated
Subscribe for More Information
07:33 EDTNLNKMerck, NewLink enter licensing, collaboration agreement for Ebola vaccine
Merck (MRK) and NewLink Genetics (NLNK) announced that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV vaccine candidate. Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate. Phase I clinical trials of the rVSV-EBOV vaccine are now underway at the Walter Reed Army Institute of Research and the NIAID at the NIH. Additional Phase I studies are underway or planned to begin in the near future at clinical research centers in Switzerland, Germany, Kenya, and Gabon in a World Health Organization-coordinated effort, and in Canada by the Canadian Immunization Research Network.
07:31 EDTNLNKMerck, NewLink Genetics enter into agreement for investigational Ebola vaccine
Subscribe for More Information
November 20, 2014
15:14 EDTNLNKTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 17, 2014
08:44 EDTNLNKNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use